Drug intelligence / Profile preview

ZAX.1400.P03

Development stage: Phase 2
Modality: Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

ZAX.1400.P03 is a topical, cream-based investigational drug being studied for the treatment of psoriasis. It is applied twice daily for 21 days in clinical trials to assess its ability to improve clinical signs of skin affected by psoriasis compared to placebo[1][2][3]. The specific mechanism of action and active ingredients have not been disclosed in available sources, but it is described as a "herbal compound" in at least one trial registry[1]. The primary indication under investigation is psoriasis.

Beyond the preview

Go deeper on ZAX.1400.P03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ZAX.1400.P03.

Explore the full profile